Get the Stockscreener App
5.985
0.42%
-0.025
After Hours:
5.99
0.005
+0.08%
Champions Oncology Inc stock is traded at $5.985, with a volume of 6,275.
It is down -0.42% in the last 24 hours and up +2.05% over the past month.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
See More
Previous Close:
$6.01
Open:
$6.01
24h Volume:
6,275
Relative Volume:
0.71
Market Cap:
$83.11M
Revenue:
$57.94M
Net Income/Loss:
$-2.34M
P/E Ratio:
-35.92
EPS:
-0.1666
Net Cash Flow:
$3.82M
1W Performance:
+0.08%
1M Performance:
+2.05%
6M Performance:
-7.92%
1Y Performance:
+3.19%
1-Day Range:
$5.85
$6.1624
1-Week Range:
$5.7601
$6.1624
52-Week Range:
$5.50
$9.6299
Champions Oncology Inc Stock (CSBR) Company Profile
Name
Champions Oncology Inc
Sector
Industry
Phone
410-369-0365
Address
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
5.985 | 83.46M | 57.94M | -2.34M | 3.82M | -0.1666 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-18-19 | Initiated | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Stock (CSBR) Latest News
Champions Oncology (CSBR) Q1 2026 Earnings: EPS Misses by Wide Margin as Company Posts LossTrading Community Hub - Newser
Champions Oncology, Inc.Common Stock (NQ: CSBR - The Chronicle-Journal
In Vivo CRO Market Size is Poised to be Valued at USD 11.83 - GlobeNewswire
Champions Onc (CSBR) Declines -1.48% Amid Market Weakness 2026-05-19Community Breakout Alerts - Newser
(CSBR) Risk Channels and Responsive Allocation - Stock Traders Daily
Champions Onc (CSBR) Q1 2026 Earnings Miss: EPS $-0.02 vs $0.09 ExpectedSocial Signal Watchlist - Newser
Champions Onc (CSBR) Q1 2026 Results Fall Short — EPS $-0.02, Revenue $N/AShort Squeeze - newser.com
Heartland Express, Inc. 8-K SEC Filing Details for May 14, 2026 – Company Information, Stock, and Compliance - Minichart
Qumulo Champions Olivia Newton-John Cancer Research Institute in New “Imagine” Fundraising Campaign - Business Wire
Cizzle Bio CEO Bill Behnke Participates in National Oncology Commercialization Panel at City of Hope's 25th Ci4CC Summit - PR Newswire
Europe Stocks: Research Stocks from Europe Stock Market - GuruFocus
(CSBR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Leading Companies Enhancing Their Presence in the Tumor Models Market - openPR.com
Patient-Derived Xenograft (PDX) Models Market (2026-2033) | - openPR.com
Champions Oncology (NASDAQ:CSBR) Shares Cross Below 200-Day Moving AverageWhat's Next? - MarketBeat
Celebration of Champions event held for children affected by cancer - fox5sandiego.com
Liquidity Mapping Around (CSBR) Price Events - Stock Traders Daily
Champions Onc (CSBR) Stock: Is It Forming a Pattern (Market Focus) 2026-04-27On Balance Volume - Newser
Champions Oncology (CSBR) Proxy Filing Summary - Quartr
Champions Oncology (NASDAQ:CSBR) Share Price Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Radiopharmaceuticals Market Size to Exceed USD 15.21 Billion By 2035 Rising Cancer Cases Boost the Market Demand - Dailyhunt
Data4Cure Presents a Foundation Model for Forward and Reverse Translation at AACR 2026 Annual Meeting - Scott Coop
Elisrasib Demonstrates High DCR in KRAS G12C+ NSCLC - The ASCO Post
Elisrasib Demonstrates High Disease Control Rate in KRAS G12C–Mutant NSCLC - The ASCO Post
Champions Onc (CSBR) Stock: Growth vs Risks (-0.98%) 2026-04-18Community Breakout Alerts - Xã Châu Thành
Cavco Industries Jumps 7.1% Amid Sector-Wide Selling - AlphaStreet
Why (CSBR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Champions Oncology (NASDAQ:CSBR) Stock Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Patient Derived Xenograft/PDX Models Market Size Expanding - openPR.com
Aug Decliners: How does Champions Oncology Inc compare to its peersMarket Activity Report & Growth Focused Investment Plans - baoquankhu1.vn
Aug Catalysts: What is Champions Oncology Incs debt to equity ratio2026 Macro Moves & Consistent Return Investment Signals - baoquankhu1.vn
Chipmakers Recap: Should I average down on ACMR stockWeekly Profit Recap & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Comedian Michael Kosta Headlines Karmanos Comedy Champions - PR Newswire
CSBR Should I Buy - Intellectia AI
Champions Oncology to present eight studies at AACR meeting By Investing.com - Investing.com Australia
Champions Oncology to present eight studies at AACR meeting - Investing.com
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026 - ACCESS Newswire
Eight cancer studies from Champions Oncology focus on drug response, resistance - Stock Titan
Bond Watch: Can Champions Oncology Inc weather a recessionWeekly Trading Summary & Verified Technical Signals - baoquankhu1.vn
Patient Derived Xenograft (PDX) Models Market is estimated - openPR.com
How does Champions Oncology Inc compare to its peers2026 Biggest Moves & Growth-Oriented Investment Plans - baoquankhu1.vn
Fennec Pharmaceuticals Inc. (FENC) stock price, news, quote and history - Yahoo Finance UK
CSBR Forecast, Price Target & Analyst Ratings | CHAMPIONS ONCOLOGY INC (NASDAQ:CSBR) - ChartMill
Understanding Momentum Shifts in (CSBR) - Stock Traders Daily
Performance Recap: What is Champions Oncology Incs debt to equity ratioMarket Risk Summary & Community Trade Idea Sharing - baoquankhu1.vn
CSBR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Market Review: How correlated is Champions Oncology Inc to the S P5002026 Setups & Long-Term Capital Growth Strategies - baoquankhu1.vn
Global Tumor Models Market Set to Soar from $2.37B in 2026 - GlobeNewswire
Datavault AI Inc. (NASDAQ: DVLT) and Demora Foundation Execute Technology Integration Agreement to Power the K-Entertainment & K-Wave Global Platform - STT Info
CSBR PE Ratio & Valuation, Is CSBR Overvalued - Intellectia AI
Datavault AI Returns a Second Time for Exclusive Investor Forum at Mar-a-Lago - NTB Kommunikasjon
Champions Oncology Inc Stock (CSBR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):